



# IMAGINE YOUR CHILD'S TAKHZYRO EXPERIENCE

CLICK TO GET STARTED 

Join the 3,250+ people since 2018\* who have chosen to help prevent hereditary angioedema (HAE) attacks before they happen.

The efficacy and safety of TAKHZYRO were evaluated in 3 clinical studies: a 6.5-month study and a 2.5-year open-label extension study in adolescents and adults, and a 12-month pediatric study.

\*Based on third-party US specialty pharmacy data for adolescent and adult patients.

## WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

## IMPORTANT SAFETY INFORMATION

**TAKHZYRO may cause serious side effects, including allergic reactions.** Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**<sup>®</sup>  
(lanadelumab-flyo) injection

# How is HAE impacting your child?

The onset of HAE symptoms can occur at any age, but studies suggest symptoms may start to appear during childhood. If you're living with HAE or caring for someone with HAE, you know the condition can be:

- Unpredictable
- Debilitating
- Life-threatening (throat attacks)



Potentially fatal throat swells have been reported in patients as young as 3 years old.

Young children may be at increased risk if a throat swell occurs due to their smaller airways.

## Help your child find the right preventive treatment that matches their needs

HAE may change over time, so your child's next attack may be different from their last. Knowing that your child's symptoms may increase in frequency and severity as they get older, you now should start thinking about using effective prevention to help manage future attacks.

**The 2020 US Hereditary Angioedema Association (HAEA) guidelines recommend regular review of any HAE management plan—including the consideration of preventive treatment in children and adults.**



### IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**<sup>®</sup>  
(lanadelumab-flyo) injection



# Takeda is committed to families living with HAE

TAKHZYRO is the **#1 prescribed HAE preventive treatment**.<sup>\*</sup> Here are a few reasons to consider it as an option for your child:



3,250+ adolescents and adults have been prescribed TAKHZYRO since 2018<sup>†</sup>



Established safety profile in a 52-week study of 21 children with HAE



Dosing once every 4 weeks for children 2 to <6 years of age or every 2 weeks for children 6 to <12 years of age



Takeda has more than 12 years of experience supporting people with HAE and their caregivers

<sup>\*</sup>Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.

<sup>†</sup>Based on third-party US specialty pharmacy data.

## IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

TAKHZYRO<sup>®</sup>  
(lanadelumab-flyo) injection

# TAKHZYRO was proven effective in adolescents and adults

The **6.5-month clinical study** included 125 people diagnosed with **HAE aged 12 years and older**. The main goal of the study was to evaluate the ability of TAKHZYRO 300 mg every 2 weeks to reduce the frequency of HAE attacks.

On average, people had

**87%** FEWER ATTACKS  
compared with placebo

**44%** of people  
**HAD ZERO ATTACKS**  
for the entire 6.5-month study  
compared with 2% of those  
taking placebo

## Established safety results

The most common side effects in the 6.5-month clinical study were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.



**Dennis**

His TAKHZYRO  
experience started in 2018

## IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**  
(lanadelumab-flyo) injection

# TAKHZYRO was studied in children

## The largest pediatric trial of any preventive treatment in HAE

The 52-week, open-label study included 21 children diagnosed with HAE aged 2 to <12 years. The main goals of the study were to:



Evaluate the safety of TAKHZYRO 150 mg taken once every 2 weeks or every 4 weeks



Measure levels of TAKHZYRO in the body for children 2 to <12 years of age

## In the 52-week study, there were:

- No serious side effects reported
- No discontinuations due to side effects
- No allergic reactions related to TAKHZYRO

In addition, levels of TAKHZYRO in the body for children 2 to <12 years of age who received 150 mg every 2 or 4 weeks were similar to those in adult patients receiving TAKHZYRO 300 mg every 2 weeks.

## IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.

## Most common related TEAEs in children taking TAKHZYRO 150 mg every 2 or 4 weeks (21 children)

- Injection site pain: **29%**
- Administration site pain: **5%**
- Injection site redness: **14%**
- Injection site reaction: **5%**
- Injection site swelling: **5%**



TEAE=treatment-emergent adverse event.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**<sup>®</sup>  
(lanadelumab-flyo) injection

# Established effectiveness of TAKHZYRO in children

Use of TAKHZYRO in children 2 to <12 years of age was supported by:

- Efficacy data from the 6.5-month study in people 12 years of age and older
- Additional data that showed similar levels of TAKHZYRO were reached in the body for adults and children


A secondary goal of the 52-week study was to measure the ability of TAKHZYRO 150 mg taken once every 2 weeks or every 4 weeks to prevent HAE attacks in 21 children 2 to <12 years of age. Decrease in HAE attacks was measured as the number of attacks before the patient started in the study compared to the number of HAE attacks after taking TAKHZYRO.

## An important note about this study

The study was not designed to understand how well TAKHZYRO works in children. The 21 children included knew they were taking TAKHZYRO. This study did not compare TAKHZYRO to another product or placebo. These details make it difficult to determine how well TAKHZYRO decreased HAE attacks in children.

## On average, children had:

- **95%** fewer HAE attacks compared to before starting the study
- **76%** of children were attack free for the entire 52-week study



Learn how TAKHZYRO works and more at [TAKHZYRO.com](https://www.takhzyro.com).

## IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**<sup>®</sup>  
(lanadelumab-flyo) injection

# Dosing that fits in your child's life

When it comes to your child's HAE treatment, it helps if the dosing schedule works with their lifestyle.

TAKHZYRO is a subcutaneous (under-the-skin) injection you or a healthcare professional can administer to your child.

Here's what you need to know about dosing with TAKHZYRO:

## Recommended dosages

For children 2 to <6 years of age, 150 mg every

**4** WEEKS

For children 6 to <12 years of age, 150 mg every

**2** WEEKS

- If your child is taking TAKHZYRO every 2 weeks and is well controlled (for example, experiencing zero attacks for more than 6 months), their doctor may consider switching them to every 4 weeks

## Administration

**3** CHOICES FOR INJECTION SITE

stomach, thigh, or upper arm

**≤1** MINUTE TO INJECT

for people 12 years of age and older\*

## IMPORTANT SAFETY INFORMATION

**TAKHZYRO may cause serious side effects, including allergic reactions.** Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

**Do not attempt to administer TAKHZYRO without first being trained by a healthcare provider.**

Administer your child's medicine with the single-dose, ready-to-use, prefilled syringe.



Not actual size.



Once your child is prescribed TAKHZYRO, you will receive training to ensure you know how to administer their therapy.

\*Most adolescents and adults in the clinical studies self-administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**<sup>®</sup>  
(lanadelumab-flyo) injection



## Tips for administering your child's dose

If your child is nervous about receiving their TAKHZYRO injection, try these suggestions. They may help make the process a little easier for everyone involved:

- **Choose the right environment**—find a clean, well-lit space where your child will feel most comfortable

### Recommendations from the CDC

- **Be honest and calm**—explain to your child, in simple terms, what they can expect. Try to remain upbeat and relaxed before, during, and after the injection
- **Consider distraction**—try to draw your child's attention away from the injection. Distractions might include a favorite song, a story, or even a silly face



#### Get dosing reminders

You can get text message reminders to help you stay on track with TAKHZYRO. [Click here](#) or text SIGNUP (o RECORDAR en español) to 36395.\*

CDC=Centers for Disease Control and Prevention.

\*Message and data rates may apply. Average of 3 messages per month. Text HELP to 36395 for more information, or text STOP to 36395 to end text reminders. View our Terms & Conditions at [engagedrx.com/tak](https://engagedrx.com/tak).

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

### IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.



**TAKHZYRO**<sup>®</sup>  
(lanadelumab-flyo) injection



# Ada shares her daughter's experience with TAKHZYRO

Ada and Kenzleigh are a mother and daughter from Texarkana, Texas, living with HAE. Kenzleigh was diagnosed when she was 6 years old. An interview with Ada tells us more about Kenzleigh's treatment journey.



**Ada,**  
Kenzleigh's mother  
and primary caregiver

**Kenzleigh,**  
taking TAKHZYRO  
for her HAE attacks

## IMPORTANT SAFETY INFORMATION (cont'd)

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

## What made you decide to start Kenzleigh on TAKHZYRO?

My doctor told me that Kenzleigh might be eligible to take part in a TAKHZYRO study for kids. I was familiar with TAKHZYRO because my sister takes it, and it works for her.

I knew right away I wanted to start her on it—especially after seeing the clinical studies. Kenzleigh was having face and throat swells. It was clear that her on-demand treatment wasn't enough. We're so grateful that the TAKHZYRO study came along at the right time for her."

## How has Kenzleigh responded to TAKHZYRO?

So far, TAKHZYRO has helped manage Kenzleigh's HAE attacks. We know we can rely on TAKHZYRO. My hope is that she can continue to take it for as long as she needs."

## What advice do you have for parents of children with HAE?

Don't give up. Your child needs you to be strong. Work with your doctor to find the solution that works best for your child. Be brave, be present, and be knowledgeable about the disease and the medicine."

The US HAEA offers advice for parents, as well as resources and connections to youth programs. Visit [haea.org](https://www.haea.org) to learn more.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

**TAKHZYRO**  
(lanadelumab-flyo) injection



## Personalized support for you and your family

### OnePath® is here to help

OnePath is a free product support program for eligible patients who have been prescribed a Takeda product. Here are some ways OnePath can support you and your child:



**Injection training.** In-home training from a specially trained nurse on how to administer TAKHZYRO® (lanadelumab-flyo)



**Financial assistance options.** Co-pay assistance for those who are eligible,\* as well as assistance with navigating insurance coverage



**Product support.** If you have any questions or need assistance, do not hesitate to reach out. OnePath is available at **1-866-888-0660**, Monday through Friday, 8:30 AM to 8:00 PM ET

\*At a minimum to be eligible, patients must have commercial insurance. Other terms and conditions apply. Contact OnePath for more information.

Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.

# TAKHZYRO is here for your child throughout their HAE journey



HAE attacks can be unpredictable, debilitating, and potentially life-threatening (throat attacks)—even for children



Established safety profile in a 52-week study—the largest pediatric trial of any preventive treatment in HAE



Dosing that fits in your child's life: once every 4 weeks for children 2 to <6 years of age or every 2 weeks for children 6 to <12 years of age

## WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

## IMPORTANT SAFETY INFORMATION

**TAKHZYRO may cause serious side effects, including allergic reactions.** Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

- wheezing
- chest tightness
- faintness
- hives
- difficulty breathing
- fast heartbeat
- rash

**Please see additional Important Safety Information throughout and full [Prescribing Information](#), including information for patients.**



©2023 Takeda Pharmaceuticals U.S.A., Inc.  
300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7  
(1-877-825-3327). All rights reserved. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO is a registered trademark of Dyax Corp., a Takeda company. OnePath is a registered trademark of Shire, a Takeda company.  
US-LANA-1483v1.0 03/23

Visit us on:



**TAKHZYRO**<sup>®</sup>  
(lanadelumab-flyo) injection